• Skip to primary navigation
  • Skip to main content
  • Skip to primary navigation
  • Skip to main content
Choose which site to search.
University of Arkansas for Medical Sciences Logo University of Arkansas for Medical Sciences
Translational Research Institute
  • UAMS Health
  • Jobs
  • Giving
  • About TRI
    • What We Offer
    • Leadership & Governance
    • Staff
    • Cite TRI
    • What is Translational Research?
    • Newsroom
  • Funding Opportunities
    • Grants
      • Pilot Award Program
      • CTSA Inter-Institutional Pilot Award Program
      • Data Science Scholars Program
      • Team Science Voucher Program
      • Winthrop P. Rockefeller Cancer Institute Rural Research Award Program
    • Scholarships
      • KL2 Mentored Research Career Development Scholar Awards
      • HSIE (TL1) Training Program
      • Implementation Science Scholar Program
      • Mini Grants for Under-Represented Faculty Researchers
      • MS-CTS Scholarship Program
    • Community
      • Community Based Participatory Research (CBPR) Scholars Program
      • Community Partners Educated as Arkansas Research Leaders (CPEARL) Program
    • Awardee Responsibilities
  • Services & Resources
    • Services
      • Biostatistics, Epidemiology and Research Design (BERD) Consultation
      • Clinical Data Repository (AR-CDR)
      • Comprehensive Informatics Resource Center (CIRC)
      • Mock Study Sections
      • Research Participant Recruitment
      • Research Support/Clinical Trials Innovation Unit (CTIU)
      • The Center for Implementation Research
    • Resources
      • ARresearch Registry
      • Center for Health Literacy
      • Data Safety Monitoring
      • UAMS Profiles
      • UAMS Rural Research Network
      • Other Resources
      • COVID-19 Research Guidelines
  • Training & Education
    • Scholarship Opportunities
      • KL2 Mentored Research Career Development Scholar Awards
      • HSIE (TL1) Training Program
      • Data Science Scholars Program
      • Implementation Science Scholar Program
      • MS-CTS Scholarship Program
      • Translational Research Innovations and Partners (TRIP) Program
    • Training & Educational Opportunities
      • innOVATION Seminar Series
      • Path 2 K Program
      • Translational Workforce Development
      • Graduate Certificate in Implementation Science
      • Master’s Program in Clinical and Translational Sciences (MS-CTS)
      • Good Clinical Practice Training
    • Video/Knowledge Library
    • Didactic Training
    • Diversity Initiatives
  • Community
    • Community Engagement Leadership
    • Community Advisory Board
    • Community Engagement Partners
      • Community Partner Celebration
    • Community Engagement Services
      • Consultations and Technical Assistance
      • Community Review Boards
      • Arkansas Community Researcher Training (ArCRT)
      • Equipment Library
    • Integrating Special Populations
    • Programs and Funding
      • Community Partners Educated as Arkansas Research Leaders (CPEARL) Program
      • Community Based Participatory Research (CBPR) Scholars Program
      • Community Scientist Academy
    • Toolkits
      • CPEARL Toolkit
      • CSA Online Toolkit
  • Events
  • Contact TRI
  1. University of Arkansas for Medical Sciences
  2. Translational Research Institute
  3. UAMS Begins Final Study of First Rapid Test for Acetaminophen Toxicity with $3.2 Million Grant

UAMS Begins Final Study of First Rapid Test for Acetaminophen Toxicity with $3.2 Million Grant


Laura James, M.D., hopes the final phase of research will lead to FDA approval of the rapid test for acetaminophen toxicity.

LITTLE ROCK —The first rapid diagnostic test for acetaminophen toxicity has cleared a major hurdle on its long road to the marketplace from the University of Arkansas for Medical Sciences (UAMS).

The test’s inventors, UAMS’ Laura James, M.D., Jack Hinson, Ph.D., and Dean Roberts, Ph.D., received a three-year, $3.2 million National Institutes of Health (NIH) Small Business Technology Transfer (STTR) grant to conduct the final phase of study before seeking Food and Drug Administration (FDA) approval of the blood test.

The grant will include the final development of the new laboratory test AcetaSTAT, a rapid assay to diagnose acetaminophen liver injury, and a clinical trial involving multiple centers to evaluate the test’s performance.

The new blood test can detect blood markers for liver injury from acetaminophen overdose in about 20 minutes. Acetaminophen is the most common drug for pain and fever, and it is the most common cause of liver failure in the United States.

“It has been a long journey, but it has been fun and exciting because we’re moving toward a big contribution in health care,” said James, who founded her company, Acetaminophen Toxicity Diagnostics (ATD) LLC, in 2006 with Roberts and Hinson. James also serves as the director of the UAMS Translational Research Institute.

ATD developed the test in conjunction with UAMS and Arkansas Children’s.

Physicians have no FDA-approved test to confirm the diagnosis of acetaminophen liver injury. They must rely on patient history and nonspecific tests of liver injury when evaluating patients with liver injury due to acetaminophen overdose.

William M. Lee, M.D., a liver disease specialist at the University of Texas Southwestern Medical Center at Dallas, is a co-investigator on the clinical trial and has been involved in prior testing of the assay. James also credits him for giving her the idea to pursue a rapid, point-of-care test.

“I have been impressed that the assay provides a reliable yes/no answer as to whether acetaminophen is responsible for the liver injury,” Lee said. “I look forward to seeing AcetaSTAT being available in any Emergency Department worldwide. Having the test will ensure that more patients receive the right diagnosis and appropriate treatment.”

James is optimistic about the assay’s prospects for FDA approval, given its past performance. She has assembled a strong, interdisciplinary team to conduct the multisite clinical trial. The team members include (in alphabetical order):

  • David Baker, CEO of ATD
  • Hans Boehringer, Ph.D., vice president, Technology Development, DCN Diagnostics; consultant
  • Ruofei Du, Ph.D., UAMS Department of Biostatistics; co-investigator
  • Maryam Garza, Ph.D., College of Medicine Department of Biomedical Informatics; co-investigator
  • Hinson, chief scientific officer; co-investigator
  • Brendan O’Farrell, Ph.D., president, DCN Diagnostics; consultant
  • Jeannette Lee, Ph.D., professor, UAMS Department of Biostatistics; co-investigator
  • Fred Prior, Ph.D., distinguished professor and chair, College of Medicine Department of Biomedical Informatics; co-investigator
  • Roberts, director of Research and Development; co-investigator

Jessica Snowden, M.D., associate professor and chief, Division of Pediatric Infectious Disease, College of Medicine Department of Pediatrics; and co-leader of the NIH-funded IDeA (Institutional Development Awards Program) States Pediatric Clinical Trials Network Data Coordinating and Operations Center; co-investigator


Posted by dsrobinson on May 25, 2022

Filed Under: Front, News, Newsroom

Translational Research Institute LogoTranslational Research InstituteTranslational Research Institute
Mailing Address: 4301 West Markham Street, Little Rock, AR 72205
Phone: (501) 686-7000
  • Facebook
  • Twitter
  • Instagram
  • YouTube
  • LinkedIn
  • Pinterest
  • Disclaimer
  • Terms of Use
  • Privacy

© 2022 University of Arkansas for Medical Sciences